Transcode Therapeutics Inc stock is traded at $1.32, with a volume of 20,841. It is down -5.06% in the last 24 hours and down -21.43% over the past month. TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
Previous Close:
$1.39
Open:
$1.43
24h Volume:
20,841
Relative Volume:
1.19
Market Cap:
$22.35M
Revenue:
-
Net Income/Loss:
-$40.36M
P/E Ratio:
-
EPS:
-$48.65
Net Cash Flow:
-$21.40M
1W Performance:
-11.41%
1M Performance:
-21.43%
6M Performance:
-81.06%
1Y Performance:
-84.32%
1-Day Range:
$1.30$1.45
1-Week Range:
$1.30$1.59
52-Week Range:
$1.30$12.60
Transcode Therapeutics Inc Stock (RNAZ) Company Profile
Name
Transcode Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
857-301-6857Address
6 LIBERTY SQUARE, BOSTON, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS